CMXCD
StimCell Energetics Inc., a biotech company, discovers, develops, and commercializes therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions in the United States. The company develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home … Read more
CMXCD (CMXCD) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of May 2025: 0.047x
Based on the latest financial reports, CMXCD (CMXCD) has a cash flow conversion efficiency ratio of 0.047x as of May 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-58.45K) by net assets ($-1.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CMXCD - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CMXCD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CMXCD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CMXCD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EKF DIAGNOSTICS
BE:LYF
|
N/A |
|
creditshelf Aktiengesellschaft
F:CSQ
|
-2.968x |
|
HHGregg Inc. (IN)
PINK:HGGG
|
N/A |
|
Alphanam M&E
VN:AME
|
N/A |
|
Petro Vietnam LPG JSC
VN:PVG
|
N/A |
|
RSID3F
SA:RSID3F
|
N/A |
|
Ismailia Misr Poultry
EGX:ISMA
|
N/A |
|
MRDIYT
BK:MRDIYT
|
N/A |
Annual Cash Flow Conversion Efficiency for CMXCD (2021–2025)
The table below shows the annual cash flow conversion efficiency of CMXCD from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-05-31 | $-1.25 Million | $-141.60K | 0.114x | -35.64% |
| 2024-05-31 | $-826.46K | $-145.90K | 0.177x | +54.70% |
| 2023-05-31 | $-2.39 Million | $-272.21K | 0.114x | -49.12% |
| 2022-05-31 | $-2.01 Million | $-450.59K | 0.224x | -36.93% |
| 2021-05-31 | $-1.58 Million | $-560.43K | 0.356x | -- |